



Irvine, K., Burt, K., & Papasouliotis, K. (2016). Evaluation of an in-practice wet chemistry analyser using canine and feline serum samples. *Journal of Veterinary Diagnostic Investigation*, 28(1), 38-45. DOI: 10.1177/1040638715618990

Peer reviewed version

License (if available):
Unspecified

Link to published version (if available):
[10.1177/1040638715618990](http://dx.doi.org/10.1177/1040638715618990)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via SAGE at <http://dx.doi.org/10.1177/1040638715618990>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/pure/about/ebr-terms.html>

1 **Evaluation of an in-practice wet-chemistry analyzer using canine and feline serum samples**

2

3 Katherine L. Irvine, Kay Burt, Kostas Papasouliotis¹

4

5 Diagnostic Laboratories, Langford Veterinary Services, School of Veterinary Sciences,
6 University of Bristol, Langford, Bristol, UK.

7

8 ¹Corresponding Author: Kostas Papasouliotis, School of Veterinary Sciences, University of
9 Bristol, Langford House, Langford, Bristol, BS40 5DU, UK. kos.papasouliotis@bristol.ac.uk

10

11 Running title: In-practice analyzer validation for canine and feline samples

12

13 **Abstract.** A wet-chemistry biochemical analyzer was assessed for in-practice veterinary use. Its
14 small size may mean a cost-effective method for low-throughput in-house biochemical analyses
15 for first-opinion practice. The objectives of our study were to determine imprecision, total
16 observed error, and acceptability of the analyzer for measurement of common canine and feline
17 serum analytes, and to compare clinical sample results to those from a commercial reference
18 analyzer. Imprecision was determined by within- and between-run repeatability for canine and
19 feline pooled samples, and manufacturer-supplied quality control material (QCM). Total
20 observed error (TE_{obs}) was determined for pooled samples and QCM. Performance was assessed
21 for canine and feline pooled samples by sigma metric determination. Agreement and errors
22 between the in-practice and reference analyzers were determined for canine and feline clinical
23 samples by Bland–Altman and Deming regression analyses. Within- and between-run precision
24 was high for most analytes, and $TE_{obs}(\%)$ was mostly lower than total allowable error.
25 Performance based on sigma metrics was good ($\sigma > 4$) for many analytes and marginal ($\sigma > 3$)
26 for most of the remainder. Correlation between the analyzers was very high for most canine
27 analytes and high for most feline analytes. Between-analyzer bias was generally attributed to
28 high constant error. The in-practice analyzer showed good overall performance, with only
29 calcium and phosphate analyses identified as significantly problematic. Agreement for most
30 analytes was insufficient for transposition of reference intervals, and we recommend that in-
31 practice–specific reference intervals be established in the laboratory.

32

33 **Key words:** Cats; dogs; instrumentation; point-of-care systems; validation studies.

34

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Introduction

Continuous advancement in diagnostic technology has increased both instrument reliability and the frequency of its in-house use in veterinary clinical practice. Hematology and biochemistry analyzers are the most frequently employed in first-opinion practice and have the advantages of being rapid and mostly cost-effective. Dry-chemistry analyzers are generally considered more cost-effective than wet-chemistry analyzers for low-throughput applications. For reference laboratories with high numbers of samples, large wet-chemistry analyzers offer significant savings given low reagent cost. The relatively rapid expiration of these reagents once opened precludes their use in low-throughput laboratories, however, because significant wastage would offset any savings. A smaller wet-reagent analyzer^a is available for veterinary in-house use, although, at present, independent performance evaluation studies have not been published, to our knowledge. The aims of this study were 1) to determine the precision, total observed error (TE_{obs}), and acceptability of the in-practice analyzer for measuring 12 common canine and feline serum biochemical analytes, and 2) to compare the results obtained from clinical samples using the in-practice analyzer to those generated from a reference commercial, high-throughput wet-chemistry analyzer.^b

51
52
53
54
55
56
57

Materials and methods

Samples

Blood samples from 66 dogs and 59 cats submitted to the Diagnostic Laboratories (University of Bristol, Langford, Bristol, UK) between March 2013 and March 2014 were included in the study. The samples included those for routine pre-anesthetic screening as well as investigation of a wide range of clinical signs and diseases. Whole blood submitted for biochemical analysis in non-anticoagulant (plain) tubes^c was allowed to clot and then centrifuged (4°C; 2,000 × g; 5 min)

58 before removal of the serum fraction. Excess serum from clinical samples following analysis was
59 frozen at -20°C for up to 1 year and used in the study with owners' consent.

60 Pooled serum samples were also created for both species using excess serum from stored
61 clinical samples. For simplicity, a single pooled sample from each species was used rather than
62 multiple samples with different concentrations for all of the different analytes. Canine and feline
63 pooled samples were created by mixing several samples containing within- or near-reference
64 concentrations for all analytes in this study, as determined by the reference chemistry analyzer.

65 Samples that were grossly hemolyzed were excluded from the study. Samples that were
66 grossly lipemic were analyzed without modification for cholesterol concentration; these samples
67 were centrifuged at high speed ($12,000 \times g$ for 5 min) and the lipid layer removed before further
68 biochemical analysis. Icteric samples with total bilirubin concentrations $>340 \mu\text{mol/L}$, as
69 measured by the reference chemistry analyzer, were excluded from the study to avoid
70 interference with phosphate measurements, according to the manufacturer's instructions.⁹

71 On the day of testing, frozen serum samples were placed in a water bath (37°C) for 5–10
72 min to thaw, and then remained at room temperature (23°C , range: $22\text{--}25^{\circ}\text{C}$) not longer than 1
73 hour before testing. Analyzer calibration, daily checks, and daily control runs were performed
74 according to the manufacturers' instructions before sample analysis.

75 **Quality control material**

76 Quality control material (QCM)^d with low, normal, and high values were included in every run
77 of samples in the reference chemistry analyzer. Two human-derived QCM (Eurocontrol N and
78 Eurocontrol P)^a were run daily on the in-practice analyzer. The analyte concentrations in
79 Eurocontrol N were all within the manufacturer-defined reference intervals. Analyte
80 concentrations in Eurocontrol P were abnormal as follows: albumin (ALB), decreased; alkaline

81 phosphatase (ALP), increased; alanine aminotransferase (ALT), increased; calcium (Ca),
82 decreased; cholesterol (Chol), increased; creatinine (Crea), increased; gamma-glutamyl
83 transferase (GGT), increased; glucose (Glu), increased; phosphate (Phos), increased; total
84 bilirubin (TBil), increased; total protein (TP), decreased; urea, increased.

85 All analyzer reagents were from the same batch to ensure consistency, and all analyses
86 were performed according to the respective manufacturers' instructions.^{2,10} The accuracy of the
87 reference chemistry analyzer methods was assessed by continuous bimonthly participation in an
88 external quality assurance program (RIQAS, <http://www.randox.com/riqas/riqas-eqa-scheme>).

89 **Analytes**

90 The following 12 analytes were assessed in this study: ALB, ALP, ALT, Ca, Chol, Crea, GGT,
91 Glu, Phos, TBil, TP, and urea. The methods employed by the 2 analyzers for measurement of
92 these analytes are shown in Table 1.

93 **Imprecision**

94 The in-practice analyzer's imprecision was assessed by within- and between-run repeatability
95 using the QCM (Eurocontrol N and P) and the canine and feline serum pools. Within-run
96 repeatability was determined by measuring each analyte in the same sample 10 times
97 sequentially within the same assay run. Between-run repeatability using the serum pools was
98 determined by measuring each analyte in the same pool each day for 5 consecutive days.⁵
99 Between-run repeatability using the QCM was determined from the daily control values
100 generated over a 2-month period (10 measurements).

101 **Method comparison and statistical analysis**

102 Individual clinical samples were run simultaneously on the 2 analyzers to minimize between-
103 analyzer error. Dilutions (1 in 2) were performed in 14 canine and 3 feline samples because the

104 original ALP (11 canine, 1 feline), ALT (2 feline), and GGT (3 canine) results were outside the
105 detection limit of the in-practice analyzer methods. All analyses were performed using the
106 graphing and statistics software Prism.^e

107 ***Imprecision, TE_{obs} , and sigma metrics***

108 Within- and between-run imprecision was determined by calculation of the coefficient of
109 variation (CV; %), where $CV = 100 \times \text{standard deviation (SD)}/\text{mean}$. $TE_{obs}(\%)$ for each analyte
110 was determined by the following formula: $TE_{obs}(\%) = 2 \times CV + \text{bias}(\%)$.⁵ Bias(%) for each
111 analyte was calculated using the QCM according to the following formula: $\text{bias} = (\text{target} -$
112 $\text{measured})/\text{target}$, where “target” is the mean analyte value reported by the manufacturer, and
113 “measured” is the mean analyte value measured by the in-practice analyzer over a 2-month
114 period.⁴ Given that 2 different QCMs (Eurocontrol N and P) were used daily, bias was
115 determined for all analytes from both controls. $TE_{obs}(\%)$ for each analyte was assessed in 2 ways:
116 1) $TE_{obs}(\%)$ values for the QCM [$TE_{obs-N}(\%)$ and $TE_{obs-P}(\%)$] were calculated for each analyte
117 using the calculated between-run CV for QCM N and P, and the N- and P-specific bias as
118 determined above, respectively; 2) species-specific $TE_{obs}(\%)$ for each analyte was calculated
119 using the between-run CV for canine and feline pools, and using QCM bias as determined
120 above.⁴ Given that bias was determined for both QCM N and P, species-specific $TE_{obs-N}(\%)$ and
121 $TE_{obs-P}(\%)$ was calculated for each analyte for comparison. An in-practice analyzer method was
122 considered acceptable if $TE_{obs} < \text{total allowable error (TE}_A)$. Because published TE_A values vary
123 throughout the literature, values were taken from both the guidelines of the American Society for
124 Veterinary Clinical Pathology and a second published study.^{5,7}

125 Sigma (σ) metric values were calculated according to the following formula: $\sigma =$
126 $(TE_A(\%) - \text{bias}(\%))/CV$.^{3,5,7} TE_A values were taken from published studies, bias was taken as the

127 bias for the QCM N, and CV as the between-run CV for the canine and feline pools.^{5,7} Where the
128 TE_A values differed between the 2 published studies, σ for both was calculated to generate $\sigma_{\text{TEA-Low}}$
129 and $\sigma_{\text{TEA-High}}$. Interpretation of σ values was performed as follows: >2: poor; >3: marginal;
130 >4: good; >5: excellent; and >6: world-class.^{6,11}

131 ***Method comparison***

132 Data from the clinical samples for all analytes in each species were assessed for normality using
133 D'Agostino and Pearson omnibus tests. When data sets from both analyzers for each analyte and
134 species were normally distributed, data were compared using a Student unpaired 2-tailed *t*-test,
135 with Welch correction for unequal variances as appropriate. A Wilcoxon rank-sum test was
136 otherwise used. Similarly, correlations between the 2 analyzers were performed using Pearson
137 correlation when data for that analyte and species were normally distributed; all other
138 correlations were performed using Spearman correlation. Correlation coefficients were
139 interpreted as: 0.9–1 very high correlation; 0.70–0.89 high correlation; 0.50–0.69 moderate
140 correlation; 0.30–0.49 low correlation; and <0.30 little, if any, correlation (Zady M, Correlation
141 and simple least squares regression, 2009, <https://www.westgard.com/lesson42.htm>).

142 Deming regression analysis was used to determine the mathematical relationship between
143 the 2 analyzers for each analyte and species, and to determine the constant (intercept) and
144 proportional (slope) errors. Bland–Altman analysis was used to assess agreement between the
145 analyzers.¹ Agreement was considered good when the 95% limits of agreement (LOA; ± 2 SD)
146 were narrow, the bias was small, and 95% points fell within the LOA.

147 **Results**

148 **Imprecision**

149 All within-run CV values were <10% (Table 2). Between-run CV values were <10% except for
150 Phos (QCM N), ALT (canine serum pool), and Ca (feline serum pool; Table 2). CV values for
151 GGT (feline serum pool) were not reported.

152 **Quality requirements**

153 All TE_{obs} values were below the lowest published TE_A for ALB, ALP, Chol, Crea, GGT, Glu,
154 and TP (Table 3). Analytes for which some TE_{obs} values were over the lower TE_A but lower than
155 the higher TE_A were ALT and TBil. For Ca and Phos, more than 1 TE_{obs} was above the higher
156 TE_A . All $\sigma_{TEA-High}$ were >3 except for Ca, Phos, and TP (feline serum pool only; Table 4). Many
157 $\sigma_{TEA-Low}$ values were also >3; TBil was the only additional analyte with a $\sigma_{TEA-Low}$ <3 in both
158 species.

159 **Method comparison using clinical samples**

160 Chol, Glu, and urea measurements were not significantly different between analyzers for clinical
161 samples in either species, whereas ALB, ALP, Phos, TBil, and TP measurements were
162 significantly different between analyzers in both canine and feline samples (Table 5).
163 Correlations between the analyzers were <0.7 for canine Phos, feline Ca, and feline GGT (Table
164 6).

165 The most substantial bias values were seen for canine ALP (242% reference median) and
166 TBil (218%), and for feline ALP (-307%), ALT (89%), GGT (110%), and TBil (250%; Tables 7,
167 8). The widest 95% LOA were observed for ALP, ALT, GGT, and TBil.

168 **Discussion**

169 Large-scale wet-chemistry analyzers are employed by most veterinary diagnostic laboratories
170 because of their speed, overall reliability, and consistency of results. The costs of running these
171 analyzers can be prohibitive for general practitioners in first-opinion practice, however,

172 especially when throughput is relatively low. Validation of smaller, less-expensive analyzers is
173 therefore of most benefit to practices who desire wet-chemistry analysis without the incumbent
174 costs.

175 The results of the repeatability study show that the within-run CV values for both QCM
176 and both serum pools were mostly $\leq 5\%$ (42/47 values), and all were $< 9\%$. The majority of
177 between-run CV values (38/47) were also $\leq 5\%$, with all values $< 14\%$. The in-practice analyzer
178 therefore has high precision for measurement of most analytes in dogs and cats, and moderate
179 precision for the remaining analytes.

180 The between-cat variation in GGT in our study, even with the inclusion of cats with
181 apparent cholestasis (based on ALP and TBil values), was relatively very low compared to that
182 for the dog. Our maximum observed feline GGT activity measured by the in-practice analyzer
183 was 12 IU/L, although TBil and ALP were normal in this cat. The maximum reference analyzer
184 GGT activity was 5 IU/L (in-practice analyzer: 4 IU/L); ALP and TBil were both markedly
185 increased in this sample. In contrast, the maximum canine GGT measured was 778 IU/L. In our
186 experience, even cats with marked cholestasis are observed to have substantially lower GGT
187 levels than other species, and milder increases following extrahepatic bile duct obstruction are
188 seen in the cat than in the dog.⁸ With such narrow between-cat variation, GGT values need to be
189 reported to at least 1 decimal place for meaningful repeatability analysis because each 1 IU/L
190 represents $\geq 8\%$ of the maximum value. GGT is measured to zero decimal places using the in-
191 practice analyzer, however, which generated very large and meaningless CV values. The results
192 were therefore excluded from the study, and dependent calculations (feline GGT TE_{obs} and σ
193 values) were not performed. This issue has been encountered in other similar studies, and results
194 were likewise excluded.⁴

195 QCM $TE_{\text{obs-N}}(\%)$ and $TE_{\text{obs-P}}(\%)$ were broadly similar for all analytes, and, with the
196 exception of canine ALT, were also broadly similar to the pooled samples. Seven of the analytes
197 (ALB, ALP, Chol, Crea, GGT, Glu, and TP) had all $TE_{\text{obs}}(\%)$ values below the lower published
198 TE_A , which demonstrates acceptability based on observed error for these methods. $TE_{\text{obs}}(\%)$ for
199 TBil and ALT were lower than the higher TE_A , which also suggests acceptability for these
200 methods. $TE_{\text{obs-P}}(\%)$ for canine urea was the only TE_{obs} value for this analyte above TE_A , but the
201 increase was small (2%) and likely to be of little significance. Several $TE_{\text{obs}}(\%)$ for Ca and all
202 $TE_{\text{obs}}(\%)$ for Phos were well above the TE_A , which suggests the in-practice analyzer methods are
203 not acceptable for measuring these analytes based on observed error.

204 The computed σ metric value for an assay and its graphical representation, the MEDx
205 chart, are performance indicators used to show assay reliability.⁶ This information complements
206 allowable error analysis and ensures that the minimum desired quality standards for an assay are
207 met. In addition, these analyses are used to determine the stringency of quality control rules for
208 that particular assay, with lower values requiring a greater number of, and more stringent, rules
209 to ensure error detection. The highest σ values in our study were generally observed for analytes
210 with $TE_{\text{obs}} < TE_A$, which is in part caused by low CV and/or bias, and relatively high TE_A .
211 Canine analytes with $\sigma_{TEA-Low}$ values >4 (good performance) were ALB, ALP, Chol, Crea, and
212 Glu, with TBil $\sigma_{TEA-High} >4$. ALT, GGT, TP, and urea were all >3 for $\sigma_{TEA-Low}$ and/or $\sigma_{TEA-High}$,
213 which suggests that the performance for measuring these analytes is likely to be sufficient but
214 with room for improvement. For feline samples, analytes with $\sigma_{TEA-Low} >4$ were ALB, Chol,
215 Crea, Glu, and urea, with $\sigma_{TEA-High} >4$ for ALP, ALT, and TBil. Ca and Phos performance in both
216 species, and TP performance in the cat, was poor or worse. No single factor was identified to
217 explain the low feline TP σ value, as bias and CV were both low. A relatively low TE_A of 10%

218 (much lower than ALB, for example) appears contributory, however, and a TE_A of 12% would
219 move the σ value to >3.

220 Ca performance is likely to be affected, at least in part, by the relatively low TE_A
221 compared to most other analytes. A low TE_A is expected for analytes that require tight biological
222 control, and so the performance requirement is high to ensure that small deviations are detected
223 accurately and reliably. Ca bias was 2% for QCM N, with between-run CV of 5% and 10% in the
224 dog and cat, respectively. This suggests that improvement in precision is required to increase the
225 σ value.

226 High TE_{obs}(%) and very poor σ values for Phos measurement appear to be the result of
227 high bias(%): QCM N generated a bias of -27%, and QCM P a bias of 14%, despite controls
228 falling within the recommended ranges given in the technical inserts. This suggests there may
229 have been a failure in calibration. Recalibration of the instrument with 2 different batches of
230 QCM N and P did not affect the Phos measurements of the QCM (not shown). Bias values for
231 the other analytes were a mixture of positive and negative, and of relatively small magnitude for
232 most analytes, which excludes errors in reconstitution of 1 or both of the QCM. Failure of
233 calibration is therefore potentially the result of either incorrect concentration of Phos in both
234 QCMs (1 is unlikely given that bias was large for both QCM but in different directions) or a
235 technical fault in the assay.

236 Correlation between the analyzers was mostly very high for canine samples, with Ca
237 showing moderate correlation and Phos showing poor correlation. The datasets for many canine
238 analytes were significantly different between the analyzers, however, and the Deming regression
239 analyses revealed that this was mostly because of constant error in the measurement of the
240 analytes by the in-practice analyzer relative to the reference analyzer. Correlations were also

241 high or very high for feline samples, with moderate correlation seen for ALB and Chol, and poor
242 for Ca and GGT. Major differences between the analyzer datasets also appeared to be the result
243 of constant rather than proportional error with the exception of GGT.

244 Agreement between the analyzers was assessed from the results of the Bland–Altman
245 analysis. For many of the analytes, $\geq 95\%$ of results fell within the 95% LOA; however, the bias
246 was too large and/or 95% LOA was too wide to be meaningful.¹ Canine Glu and TP, and feline
247 TP, had a small mean bias and relatively narrow LOA, as well as $\geq 95\%$ results within the 95%
248 LOA, consistent with good agreement. Agreement for the remaining analytes was considered
249 unacceptable.

250 Our study had some limitations. Ideally, precision, TE_{obs} , and σ metrics are calculated for
251 2 or 3 different analyte levels (low, within-reference, and high) to show performance over the
252 range of clinical samples. In our study, we determined 1 precision, TE_{obs} , and σ metric value for
253 each analyte given the use of a single pooled sample for each species. It must also be noted that
254 veterinary TE_A values are generally based on results from canine studies, and all TE_A values in
255 this study were defined for dogs. It is therefore possible that these values are not always
256 appropriate for cats when reference intervals differ significantly between species. Complete
257 validation of a method should include reportable range, recovery, and interference
258 measurements. For simplicity, these were not performed during this study, and it is
259 recommended that these be determined prior to clinical use. Last, duplicate measurement of
260 analytes in the clinical samples may have improved agreement between the analyzers. Were the
261 interchangeability of reference intervals between the analyzers of critical importance, this would
262 have been preferred; for the purposes of this study and other studies, it was not necessary.⁴

263 **Authors' contributions**

264 KL Irvine contributed to design of the study; contributed to acquisition, analysis, and
265 interpretation of data; drafted the manuscript; and critically revised the manuscript. K Burt
266 contributed to acquisition of data and drafted manuscript. K Papasouliotis contributed to
267 conception and design of the study; contributed to acquisition, analysis, and interpretation of
268 data; drafted manuscript; and critically revised the manuscript. All authors gave final approval
269 and agreed to be accountable for all aspects of the work in ensuring that questions relating to the
270 accuracy or integrity of any part of the work are appropriately investigated and resolved.

271 **Sources and manufacturers**

- 272 a. KeyLab, BPC BioSed SrL, Rome, Italy.
- 273 b. Konelab PRIME 60i, Thermo Scientific Oy, Vantaa, Finland.
- 274 c. BD, Franklin Lakes, NJ.
- 275 d. Bio-Stat Diagnostic Ltd., Worcestershire, UK.
- 276 e. GraphPad Software Inc., San Diego, CA.

277 **Declaration of conflicting interests**

278 The author(s) declared no potential conflicts of interest with respect to the research, authorship,
279 and/or publication of this article.

280 **Funding**

281 The study was funded by HORIBA Medical of HORIBA UK Ltd., Northampton, UK.

282 **References**

- 283 1. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of
284 clinical measurement. *Lancet* 1986;1:307–310.

- 285 2. Farr AJ, Freeman KP. Quality control validation, application of sigma metrics, and
286 performance comparison between two biochemistry analyzers in a commercial veterinary
287 laboratory. *J Vet Diagn Invest* 2008;20:536–544.
- 288 3. Flatland B, et al. Analytical performance of a dry chemistry analyzer designed for in-clinic
289 use. *Vet Clin Pathol* 2014;43:206–217.
- 290 4. Harr KE, et al. ASVCP guidelines: allowable total error guidelines for biochemistry. *Vet Clin*
291 *Pathol* 2013;42:424–436.
- 292 5. Nevalainen D, et al. Evaluating laboratory performance on quality indicators with the Six
293 Sigma scale. *Arch Pathol Lab Med* 2000;124:516–519.
- 294 6. Rishniw M, et al. The quality of veterinary in-clinic and reference laboratory biochemical
295 testing. *Vet Clin Pathol* 2012;41:92–109.
- 296 7. Tennant B. Hepatic Function. In: Kaneko J, et al., ed. *Clinical Biochemistry of Domestic*
297 *Animals*. 6th ed. London, UK: Academic Press, 2008:379–412.
- 298 8. Westgard JO. A method evaluation decision chart (MEDx chart) for judging method
299 performance. *Clin Lab Sci* 1995;8:277–283.
- 300

301 **Table 1.** Methods employed by the in-practice and reference analyzers for biochemical
 302 analysis.*

Analyte	In-practice analyzer	Reference analyzer
ALB	Bromocresol green	Bromocresol green
ALP	DGKC at 37°C, DEA	IFCC at 37°C, AMP buffer
ALT	IFCC (without P5P) at 37°C	IFCC (with P5P) at 37°C
Ca	Arsenazo	Arsenazo
Chol	GOD-PAP	Cholesterol oxidase/peroxidase colorimetric
Crea	Jaffé modified	Enzymatic colorimetric
GGT	IFCC (GLUCANA) at 37°C	IFCC (GLUCANA) at 37°C
Glu	GOD-PAP	Hexokinase
Phos	Ammonium molybdate	Ammonium molybdate
TBil	Acid diazo coupling	Acid diazo coupling
TP	Biuret modified	Biuret
Urea	Urease	Urease

303 * ALB = albumin; ALP = alkaline phosphatase; ALT = alanine aminotransferase; Ca = calcium;
 304 Chol = cholesterol; Crea = creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos
 305 = phosphate; TBil = total bilirubin; TP = total protein; DGKC = German Society for Clinical
 306 Chemistry (now German Society for Clinical Chemistry and Laboratory Medicine, Bonn,
 307 Germany); DEA = diethanolamine; International Federation of Clinical Chemistry and
 308 Laboratory Medicine (Milano, Italy); AMP = 2-amino-2-methyl-1-propanol; P5P = pyridoxine-
 309 5-phosphate; GLUCANA = γ -glutamyl-3-carboxy-4-nitroanilide; GOD-PAP = Trinder oxidase-
 310 peroxidase-aminophenazone.

311

312 **Table 2.** Within- and between-run precision data for quality control material (Eurocontrol N and
 313 Eurocontrol P; QCM N and P, respectively) and serum pools using the in-practice analyzer.*

Analyte	Within-run CV (%)				Between-run CV (%)			
	QCM N	QCM P	Canine pool	Feline pool	QCM N	QCM P	Canine pool	Feline pool
ALB	0.98	1.80	1.34	2.21	2.18	1.17	2.16	2.46
ALP	2.80	1.59	3.11	2.87	2.19	1.55	1.81	5.22
ALT	8.22	2.40	3.76	4.79	2.68	1.90	11.71	4.98
Ca	1.75	1.12	1.88	0.93	1.96	1.07	4.76	10.61
Chol	1.84	1.64	1.78	2.03	1.41	2.17	0.24	1.74
Crea	1.62	0.75	3.51	1.49	5.68	4.20	2.33	1.58
GGT	2.95	2.26	7.44	NA	1.29	2.79	5.08	NA
Glu	2.43	3.08	1.48	2.22	2.23	2.31	1.66	2.12
Phos	5.07	1.77	2.96	3.19	13.72	7.21	5.39	4.09
TBil	2.91	1.13	3.51	6.77	4.51	1.30	3.17	7.28
TP	1.90	1.93	2.58	2.61	0.54	2.70	1.88	2.97
Urea	2.70	2.52	5.48	3.10	5.15	1.58	3.88	1.96

314 * CV = coefficient of variation; ALB = albumin; ALP = alkaline phosphatase; ALT = alanine
 315 aminotransferase; Ca = calcium; Chol = cholesterol; Crea = creatinine; GGT = gamma-glutamyl
 316 transferase; Glu = glucose; Phos = phosphate; TBil = total bilirubin; TP = total protein; NA = not
 317 applicable (see Discussion section).

318

319 **Table 3.** Quality control material (QCM) bias(%) and total observed error [TE_{obs}(%)] for the in-
 320 practice analyzer, together with published total allowable error (TE_A).*

Analyte	QCM				Serum pools				TE _A †
	Bias-N	Bias-P	TE _{obs} -N	TE _{obs} -P	Dog		Cat		
					TE _{obs} -N	TE _{obs} -P	TE _{obs} -N	TE _{obs} -P	
ALB	-2.0	-9.5	6	12	6	14	7	14	15, 25
ALP	4.0	1.4	8	4	8	5	14	12	25§, 25
ALT	-7.3	2.5	13	6	31	26	17	12	25, 50
Ca	2.5	9.2	6	11	12	19‡	24‡	30‡	10, 14
Chol	-0.8	0.6	4	5	1	1	4	4	20
Crea	-6.0	-3.9	17	12	11	9	9	7	17, 20
GGT	-2.7	-7.9	5	13	13	18	NA	NA	20
Glu	-4.3	-5.1	9	10	8	8	8	9	20, 20
Phos	-27.3	14.4	55‡	29‡	38‡	25‡	35‡	23‡	15, 20
TBil	-17.5	-11.2	27	14	24	18	32	26	30‡, 50
TP	2.9	4.2	4	10	7	8	9	10	10, 10
Urea	-1.8	-10.3	12	13	10	18‡	6	14	12, 16

321 * N, P = Eurocontrol N and P^a, respectively; ALB = albumin; ALP = alkaline phosphatase; ALT
 322 = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea = creatinine; GGT = gamma-
 323 glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total bilirubin; TP = total protein;
 324 NA = not applicable.

325 † Published TE_A values.^{5,7}

326 ‡ TE_{obs} > TE_A.

327 § 20% desirable.⁵

328 † 25% desirable.⁵

329

330 **Table 4.** Sigma (σ) values for canine and feline pooled serum measured using the in-practice
 331 analyzer.*

Analyte	Canine pooled serum		Feline pooled serum	
	$\sigma_{TEA-Low}$	$\sigma_{TEA-High}$	$\sigma_{TEA-Low}$	$\sigma_{TEA-High}$
ALB	6.0	10.6	5.3	9.3
ALP	8.8	11.6	3.1	4.0
ALT	1.5	3.6	3.6	8.6
Ca	1.6	2.4	0.7	1.1
Chol	79.9	NA	11.0	NA
Crea	4.7	6.0	6.9	8.8
GGT	3.4	NA	NA	NA
Glu	9.5	NA	7.4	NA
Phos	-2.3	-1.3	-3.0	-1.8
TBil	2.4	10.2	1.0	4.5
TP	3.8	NA	2.4	NA
Urea	2.6	3.7	5.2	7.3

332 * TE_A = total allowable error; ALB = albumin; ALP = alkaline phosphatase; ALT = alanine
 333 aminotransferase; Ca = calcium; Chol = cholesterol; Crea = creatinine; GGT = gamma-glutamyl
 334 transferase; Glu = glucose; Phos = phosphate; TBil = total bilirubin; TP = total protein; NA = not
 335 applicable (cannot be calculated).

336

337 **Table 5.** Measurement of analytes from canine clinical samples using the in-practice and
 338 reference analyzers.*

Analyte	<i>r</i>	In-practice analyzer		Reference analyzer		<i>P</i>
		Median	Range	Median	Range	
ALB (g/L)	0.91	33.5	15.9–44.9	26.8	12.8–25.8	<0.0001
ALP (IU/L)	1.00	240	25–5400	115	8–2793	0.002
ALT (IU/L)	0.97	54	8–364	53	6–447	0.800
Ca (mmol/L)	0.78	2.47	1.01–3.34	2.65	1.17–3.78	0.009
Chol (mmol/L)	0.98	5.54	1.79–15.39	5.35	1.76–17.58	0.522
Crea (μmol/L)	0.93	87.4	45.4–321.0	71.0	33.0–308.0	0.008
GGT (IU/L)	0.94	6	1–778	6	0–815	0.878
Glu (mmol/L)	0.93	4.89	0.24–19.50	5.00	0.40–18.80	0.891
Phos (mmol/L)	0.49	1.70	0.24–2.80	1.52	0.58–3.79	0.028
TBil (μmol/L)	0.70	20.0	1.2–87.0	7.2	2.0–79.2	<0.0001
TP (g/L)	0.93	64.3	28.5–83.6	59.3	27.2–80.2	0.002
Urea (mmol/L)	0.97	6.7	2.2–35.6	5.9	2.0–34.5	0.277

339 * *P* = significance of difference between the datasets for the 2 analyzers; ALB = albumin; ALP =
 340 alkaline phosphatase; ALT = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea =
 341 creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total
 342 bilirubin; TP = total protein.

343

344 **Table 6.** Measurement of analytes from feline clinical samples using the in-practice and
 345 reference analyzers.*

Analyte	<i>r</i>	In-practice analyzer		Reference analyzer		<i>P</i>
		Median	Range	Median	Range	
ALB (g/L)	0.71	33.7	22.3–47.3	27.4	16.8–33.6	<0.0001
ALP (IU/L)	0.93	72	3–1133	28	5–385	<0.0001
ALT (IU/L)	0.88	35	2–820	61	23–960	0.0008
Ca (mmol/L)	0.62	2.46	1.60–3.37	2.50	1.92–3.22	0.175
Chol (mmol/L)	0.77	4.17	2.31–9.20	4.00	1.52–8.76	0.673
Crea (μmol/L)	0.98	119.9	36.5–564.3	106.0	27.0–559.0	0.134
GGT (IU/L)	0.25	2	1–12	1	1–5	0.002
Glu (mmol/L)	0.86	5.35	2.59–11.63	5.40	2.60–13.20	0.880
Phos (mmol/L)	0.81	1.30	0.90–2.60	1.58	0.99–3.19	<0.0001
TBil (μmol/L)	0.86	10.1	3.5–367.0	4.4	1.9–207.0	<0.0001
TP (g/L)	0.82	71.2	47.1–91.8	67.0	42.7–87.5	0.018
Urea (mmol/L)	0.95	12.2	3.90–34.57	11.20	3.90–36.70	0.087

346 * *P* = significance of difference between the data sets for the 2 analyzers; ALB = albumin; ALP
 347 = alkaline phosphatase; ALT = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea
 348 = creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total
 349 bilirubin; TP = total protein.

350

351 **Table 7.** Proportional error (slope), constant error (y-intercept), and bias for canine samples
 352 measured using the in-practice analyzer and relative to the reference analyzer.*

Analyte	Deming regression				Bland–Altman		
	Slope	95% CI	y-intercept	95% CI	Bias	95% LOA	% in LOA
ALB (g/L)	1.23	1.11–1.36	0.43	–2.92 to 3.79	6.5	2.2 to 10.8	91
ALP (IU/L)	1.94	1.90–1.98	17.48	–4.53 to 39.49	278	–531 to 1087	95
ALT (IU/L)	0.83	0.78–0.87	8.87	2.78 to 14.95	–8	–58 to 43	91
Ca (mmol/L)	1.09	0.90–1.27	–0.40	–0.88 to 0.08	–0.18	–0.64 to 0.28	98
Chol (mmol/L)	1.01	0.96–1.06	0.22	–0.11 to 0.56	0.28	–0.83 to 1.39	95
Crea (μmol/L)	1.07	1.01–1.14	8.86	2.34 to 15.40	15.2	–9.4 to 39.8	92
GGT (IU/L)	0.98	0.96–0.99	1.20	–0.34 to 2.74	0.5	–12.4 to 13.4	97
Glu (mmol/L)	1.05	1.00–1.11	–0.20	–0.50 to 0.09	0.06	–0.94 to 1.06	100
Phos (mmol/L)	0.61	0.41–0.81	0.75	0.41 to 1.10	0.11	–0.82 to 1.05	97
TBil (μmol/L)	1.80	1.40–2.19	8.01	2.21 to 13.81	15.7	–7.1 to 38.5	95
TP (g/L)	1.19	1.11–1.28	–5.46	–10.58 to 0.33	5.6	–1.7 to 12.8	95
Urea (mmol/L)	1.07	1.03–1.11	0.21	–0.17 to 0.58	0.71	–1.19 to 2.62	98

353 * CI = confidence interval; LOA = limits of agreement; ALB = albumin; ALP = alkaline
 354 phosphatase; ALT = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea =
 355 creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total
 356 bilirubin; TP = total protein.
 357

358 **Table 8.** Proportional error (slope), constant error (y-intercept), and bias for feline samples
 359 measured using the in-practice analyzer and relative to the reference analyzer.

Analyte	Deming regression				Bland–Altman		
	Slope	95% CI	y-intercept	95% CI	Bias	95% LOA	% in LOA
ALB (g/L)	1.51	1.11–1.90	–7.28	–17.90 to 3.35	6.3	–0.2 to 12.9	90
ALP (IU/L)	2.63	2.50–2.76	–3.95	–15.94 to 8.05	86	–151 to 323	97
ALT (IU/L)	0.66	0.59–0.74	–4.27	–23.56 to 15.03	–54	–247 to 139	97
Ca (mmol/L)	1.62	1.07–2.17	–1.63	–3.02 to –0.24	–0.08	–0.65 to 0.49	97
Chol (mmol/L)	1.14	0.93–1.34	–0.41	–1.30 to 0.47	0.15	–1.38 to 1.67	95
Crea (μmol/L)	1.02	0.99–1.06	12.37	6.64 to 18.10	15.5	–9.1 to 40.0	93
GGT (IU/L)	5.24	1.16–9.32	–5.94	–13.96 to 2.08	1.1	–3.1 to 5.3	98
Glu (mmol/L)	1.01	0.89–1.13	0.00	–0.73 to 0.74	0.08	–1.40 to 1.55	97
Phos (mmol/L)	0.80	0.70–0.91	0.07	–0.11 to 0.24	–0.26	–0.66 to 0.15	93
TBil (μmol/L)	1.62	1.53–1.72	2.07	–1.31 to 5.46	11.0	–31.3 to 53.2	98
TP (g/L)	1.02	0.83–1.21	2.70	–10.08 to 15.49	4.0	–6.6 to 14.5	97
Urea (mmol/L)	1.07	0.99–1.15	0.67	–0.40 to 1.75	1.48	–2.15 to 5.11	98

360 * CI = confidence interval; LOA = limits of agreement; ALB = albumin; ALP = alkaline

361 phosphatase; ALT = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea =

362 creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total

363 bilirubin; TP = total protein.